Jan 07, 2025
BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial
Oct 07, 2024
BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients
Aug 21, 2024
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
Jul 29, 2024
BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial
May 29, 2024
BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development
May 28, 2024
BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®
Dec 06, 2020
BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020
Nov 11, 2020
BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting
Sep 01, 2020
BerGenBio to Present at Upcoming Investor Conferences
Aug 10, 2020
BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation
Jul 20, 2020
Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I/II Study Assessing Selective AXL Inhibitor Bemcentinib
Jul 07, 2020
BerGenBio to Present at Digital Novel Coronavirus Investment Forum
Jun 25, 2020
BerGenBio Announces Positive Interim Clinical and Translational Data from Phase II Trial of Bemcentinib in Combination with Keytruda® in Checkpoint Inhibitor Refractory NSCLC Patients
Jun 24, 2020
BerGenBio Announces Change to Presentation Time at Next Gen Immuno-Oncology Congress
Jun 02, 2020
Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial
May 19, 2020
BerGenBio ASA: Results for the First Quarter 2020
May 13, 2020
BerGenBio ASA: Invitation to First Quarter 2020 Results Webcast Presentation
May 05, 2020
BerGenBio Raises Nok500m (EUR45.4m) via an Over Subscribed Private Placement
Apr 28, 2020
BerGenBio's Bemcentinib Selected to Be Fast-tracked As Potential Treatment for COVID-19 Through New National UK Government Clinical Trial Initiative
Jan 15, 2020
BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC Patients Progressing on Immune Checkpoint Inhibitors